US Patent Issued to NEURODAWN PHARMACEUTICAL on Oct. 27 for "Use of a class of 1,4-dihydro-naphthyridine derivatives in treatment of tumors" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,404, issued on Oct. 27, was assigned to NEURODAWN PHARMACEUTICAL Co. LTD. (Nanjing, China).

"Use of a class of 1,4-dihydro-naphthyridine derivatives in treatment of tumors" was invented by Zhengping Zhang (Nanjing, China), Fulong Li (Nanjing, China), Lei Wang (Nanjing, China), Rong Chen (Nanjing, China), Weidong Yang (Nanjing, China), Fang Fang (Nanjing, China), Wenji An (Nanjing, China), Yao Hua (Nanjing, China) and Lin Feng (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the use of a class of 1,4-dihydro-naphthyridine derivatives in the treatment of tumors."

The patent was filed on Nov. 21, 2022, un...